Sensitivity towards HDAC inhibition is associated with RTK/MAPK pathway activation in gastric cancer.
HDACi
MAPK
gastric cancer
organoids
Journal
EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380
Informations de publication
Date de publication:
10 10 2022
10 10 2022
Historique:
revised:
01
08
2022
received:
19
01
2022
accepted:
02
08
2022
pubmed:
23
8
2022
medline:
12
10
2022
entrez:
22
8
2022
Statut:
ppublish
Résumé
Gastric cancer ranks the fifth most common and third leading cause of cancer-related deaths worldwide. Alterations in the RTK/MAPK, WNT, cell adhesion, TP53, TGFβ, NOTCH, and NFκB signaling pathways could be identified as main oncogenic drivers. A combination of altered pathways can be associated with molecular subtypes of gastric cancer. In order to generate model systems to study the impact of different pathway alterations in a defined genetic background, we generated three murine organoid models: a RAS-activated (Kras
Identifiants
pubmed: 35993110
doi: 10.15252/emmm.202215705
pmc: PMC9549728
doi:
Substances chimiques
Proteome
0
Transforming Growth Factor beta
0
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15705Informations de copyright
© 2022 The Authors. Published under the terms of the CC BY 4.0 license.
Références
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Curr Opin Oncol. 2012 Mar;24(2):123-9
pubmed: 22314615
Nat Med. 2015 May;21(5):449-56
pubmed: 25894828
Front Oncol. 2021 Mar 11;11:638360
pubmed: 33777798
Nat Commun. 2018 Mar 8;9(1):1012
pubmed: 29520031
Acta Pathol Microbiol Scand. 1965;64:31-49
pubmed: 14320675
Gut. 2015 Oct;64(10):1650-68
pubmed: 26342014
Cancer Res. 2009 May 15;69(10):4286-93
pubmed: 19401449
Semin Cancer Biol. 2003 Feb;13(1):49-58
pubmed: 12507556
Cell. 2004 Dec 17;119(6):847-60
pubmed: 15607980
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Gut. 2019 Feb;68(2):207-217
pubmed: 29703791
Nat Med. 2015 Mar;21(3):256-62
pubmed: 25706875
J Mol Med (Berl). 2017 Jul;95(7):729-738
pubmed: 28391362
Cell. 2015 Jan 15;160(1-2):299-312
pubmed: 25533785
Nature. 2009 May 14;459(7244):262-5
pubmed: 19329995
Nat Cell Biol. 2016 Mar;18(3):246-54
pubmed: 26911908
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Bioinformatics. 2017 Jan 1;33(1):135-136
pubmed: 27605098
JAMA. 2017 May 9;317(18):1844-1853
pubmed: 28492898
Int J Cancer. 2018 Oct 15;143(8):2053-2064
pubmed: 29756206
Gastroenterology. 2013 Sep;145(3):554-65
pubmed: 23684942
Mech Dev. 2002 Jul;115(1-2):53-62
pubmed: 12049767
Genes Cancer. 2011 Mar;2(3):261-74
pubmed: 21779497
PLoS Genet. 2006 Sep 15;2(9):e146
pubmed: 17002498
Mol Cancer Ther. 2006 May;5(5):1239-47
pubmed: 16731756
J Gastrointest Oncol. 2017 Jun;8(3):418-429
pubmed: 28736629
BMC Dev Biol. 2020 Feb 26;20(1):4
pubmed: 32098630
EMBO Mol Med. 2022 Oct 10;14(10):e15705
pubmed: 35993110
NPJ Precis Oncol. 2021 Apr 12;5(1):30
pubmed: 33846504
Oncotarget. 2015 Dec 8;6(39):41692-705
pubmed: 26497680
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
BMC Cancer. 2014 Jul 30;14:552
pubmed: 25079037
Anticancer Res. 2010 Nov;30(11):4673-7
pubmed: 21115922
Nature. 2010 Mar 18;464(7287):427-30
pubmed: 20179705
Eur J Gynaecol Oncol. 2002;23(5):390-6
pubmed: 12440809
Front Oncol. 2018 Mar 29;8:92
pubmed: 29651407
Int J Biochem Cell Biol. 2007;39(7-8):1476-82
pubmed: 17499002
Mol Cancer Ther. 2018 Jan;17(1):17-25
pubmed: 29079711
Nature. 2010 Mar 18;464(7287):431-5
pubmed: 20130576
J Pathol. 2022 Aug;257(5):607-619
pubmed: 35373359
Lancet. 2020 Aug 29;396(10251):635-648
pubmed: 32861308
Genes Dev. 2001 Dec 15;15(24):3243-8
pubmed: 11751630
NPJ Precis Oncol. 2018 Mar 7;2(1):7
pubmed: 29872725
Science. 2018 Feb 23;359(6378):920-926
pubmed: 29472484
Cell. 2013 Oct 10;155(2):357-68
pubmed: 24120136
Oncotarget. 2017 Jan 17;8(3):3980-4000
pubmed: 28002810